Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | MATK | P42679 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093009 | 0.91 | PIM3 (0.44) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2094434 | 0.91 | PIM3 (0.44) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9535386 | 0.86 | LMNA (0.60) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2092612 | 0.86 | LMNA (0.44) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2092200 | 0.85 | PIM3 (0.52) | PIM3PIM1MAPKAPK3RPS6KB1MATK | |
| SCHEMBL10824682 | 0.79 | LMNA (0.46) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9538782 | 0.77 | ADORA2A (0.43) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2093405 | 0.76 | CSNK2A1 (0.42) | LMNACYP2C9PIM3PIM1MAPKAPK3 | |
| SCHEMBL11017308 | 0.76 | CASP1 (0.45) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL2095834 | 0.76 | CSNK2A1 (0.42) | CYP2C9PIM3PIM1MAPKAPK3RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | LMNA 2661/4885CYP2C9 45/4885ATP6V1B2 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.